查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012678

異位性皮膚炎治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、給藥方法、患者年齡層和分銷管道分類）

Atopic Dermatitis Drugs Market by Drug Class, Route Of Administration, Mode Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，異位性皮膚炎治療市場價值將達到 91.8 億美元，到 2026 年將成長至 98.4 億美元，到 2032 年將達到 157.8 億美元，複合年成長率為 8.04%。

主要市場統計數據
基準年 2025 91.8億美元
預計年份：2026年 98.4億美元
預測年份 2032 157.8億美元
複合年成長率 (%) 8.04%

本書簡明扼要、引人入勝地介紹了異位性皮膚炎治療領域的最新進展，重點在於科學進步、未滿足的需求和策略重點。

異位性皮膚炎已從一種主要以緩解症狀為治療目標的皮膚病發展成為一個擁有多種緩解疾病治療方法的複雜治療領域。免疫學的進步闡明了關鍵的發病機轉通路，使得針對白細胞介素訊號通路和Janus激酶通路的治療方法成為可能。同時，外用製劑和給藥技術的改進提高了患者的用藥依從性和耐受性。同時，保險公司的審查、臨床實踐中的安全性證據以及患者的期望正在重塑新療法和現有治療方法在臨床應用中的優先順序。

生物製劑、小分子藥物、數位醫療和報銷壓力正在推動變革性變化，重塑異位性皮膚炎的醫療保健服務和治療模式。

在異位性皮膚炎領域，正在發生變革性的變化，這些變化正在影響藥物的發現、開發和商業化過程。針對特定細胞激素的生物製藥正在為中重度疾病的治療樹立新的標準，從而推動了對下一代生物製藥和針對更廣泛患者群體的口服小分子藥物的投資。同時，關於小分子免疫調節劑的安全性討論和上市後證據正在影響與監管機構的對話以及臨床指南的製定，迫使生產商修訂附加檔、監測策略和患者選擇標準。

基於 2025 年美國可能徵收關稅的情景，對供應鏈、價格趨勢、臨床准入和生產策略累積影響分析。

如果新的關稅措施在2025年實施，其累積影響將波及整個異位性皮膚炎治療生態系統，涵蓋生產、採購和病患取得途徑。活性成分和某些特殊添加劑的採購依賴複雜的國際供應鏈，其中包括關鍵的生產基地。關稅導致的原料成本上漲可能會促使製造商重新評估其供應商組合，加快近岸外包，或重新談判合約條款，以維持產品價格可負擔性和供應穩定性。重要的是，這些供應方的應對措施將與經銷商和批發商為緩解利潤率壓縮、維持庫存週轉而採取的策略同步進行。

以細分市場為中心的洞察，揭示藥物類別、給藥途徑和方法、分銷管道以及患者年齡層如何影響臨床應用和商業性策略。

從詳細的細分觀點，臨床特徵和商業性機制如何影響治療方法的採納和患者療效至關重要。依藥物類別分析產品，全身性治療藥物可分為生物製劑和小分子免疫抑制劑，而局部治療藥物包括Calcineurin抑制劑、皮質類固醇、磷酸二酯酶-4抑制劑和維生素D類似物。每種藥物都有其獨特的療效、安全性以及依從性考量。因此，策略規劃必須認知到，生物製劑通常需要注射給藥和監測所需的配套設施，而局部治療藥物則需要持續的患者教育和製劑創新，以提高皮膚滲透性和耐受性。

一項區域分析，比較了美洲、歐洲、中東和非洲以及亞太地區影響異位性皮膚炎 (AD) 治療的法規、獲取途徑和戰略夥伴關係的趨勢。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的監管方式、支付方預期和夥伴關係機會，每個地區都面臨獨特的策略挑戰。在美洲，監管路徑和支付系統強調能夠證明藥物對患者俱有顯著益處的證據，並且越來越重視利用真實世界數據來檢驗的長期安全性和有效性。在該地區運作的相關人員需要建立強力的價值提案和上市後證據基礎，以支持處方藥的上市和持續治療，同時也要應對分散的支付方環境。

競爭資訊揭示了領先的製藥和生物技術公司如何在異位性皮膚炎領域推進其研發管線、夥伴關係和商業化策略。

主要企業正朝著幾個明確的策略主題邁進：差異化科學、可操作的證據生成以及生態系統夥伴關係。推進生物製藥計畫的公司正專注於目標有效性、透過直接比較獲得的耐受性優勢以及長期安全性監測，以使自身產品與現有和新進入者區分開來。同樣，開發小分子免疫調節劑的公司正在改進劑量最佳化、監測策略和風險管理計劃，以解決安全性問題並擴大其在成人和兒童人群中的適應症覆蓋範圍。同時，專注於局部治療的公司正在致力於製劑科學，以增強皮膚滲透性、減少刺激性，並透過更符合人體美容需求的劑型來提高患者的依從性。

為行業領導者提供切實有效的建議，以最佳化異位性皮膚炎 (AD) 的研發優先事項、供應彈性、定價策略和以患者為中心的商業化。

產業領導者應優先考慮一系列切實可行的舉措，將科學研究機會與實際應用結合。首先，投資於差異化的臨床開發策略，將基於機制的證據與穩健的安全監測和真實世界數據（RWE）計劃相結合。這將有助於與監管機構合作，與支付方對話，同時也能增強臨床醫師的信心。其次，透過供應商多元化、評估近岸生產方案以及在採購合約中加入緊急時應對計畫來增強供應鏈韌性，從而減輕外部政策和物流衝擊的影響。

一份詳盡的調查方法說明，解釋瞭如何將資料來源、分析方法、檢驗協議和見解整合到可操作的行業指導中。

本報告的分析整合了同儕審查文獻、監管指導文件、臨床試驗註冊資料、企業資訊披露資訊和縱向安全性資料集，建構了一個全面的證據基礎。透過結構化訪談，我們整合了來自臨床意見領袖、支付方顧問和供應鏈專家的定性見解，以闡釋定量研究結果並揭示其營運意義。分析方法結合了主題整合和情境分析，旨在探討政策、定價、供應鏈突發事件及其對臨床應用和可近性的影響。

總之，綜合分析提取了臨床、監管和商業職能部門相關人員的關鍵策略意義、風險考量和機會窗口。

總之，目前異位性皮膚炎治療的特點是科學發展迅速、藥物取得途徑不斷變化，以及臨床差異化與商業性可行性之間日益複雜的相互作用。戰略贏家將是那些能夠將基於機制的顯著優勢與循證醫學、可靠的生產製造以及跨管道病人參與方案相結合的公司。風險因素包括新治療方法的安全監測要求、影響供應鏈和定價的政策變化，以及需要根據不同的區域醫療保健系統調整治療方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 異位性皮膚炎治療市場：依藥物類別分類

  • 全身
    • 生物製藥
    • 低分子量免疫抑制劑
  • 外用藥物
    • Calcineurin抑制劑
    • 皮質類固醇
    • PDE4抑制劑
    • 維生素D類似物

第9章：異位性皮膚炎治療市場：依給藥途徑分類

  • 奶油
  • 凝膠
  • 洗劑
  • 軟膏

第10章：依給藥途徑分類的異位性皮膚炎治療藥物市場

  • 注射藥物
    • 預填充式注射器
    • 管瓶
  • 口服

第11章：依患者年齡層分類的異位性皮膚炎治療市場

  • 成人版
  • 老年人
  • 兒童

第12章 異位性皮膚炎治療市場：依分銷管道分類

  • 醫院藥房
    • 私立醫院的藥房
    • 公立醫院藥房
  • 網路藥房
    • 數位健康平台
    • 電子商務平台
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第13章 異位性皮膚炎治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 異位性皮膚炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 異位性皮膚炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國異位性皮膚炎治療市場

第17章：中國特異性皮膚炎治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Almirall, SA
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Bausch Health Companies Inc.
  • BiomX Inc.
  • Bristol-Myers Squibb Company
  • Dermavant Sciences Inc.
  • Eli Lilly and Company
  • Galderma Group AG
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Intas Pharmaceuticals Ltd.
  • Kiniksa Pharmaceuticals, Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • LEO Pharma A/S
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Vanda Pharmaceuticals, Inc.
Product Code: MRR-436901065D12

The Atopic Dermatitis Drugs Market was valued at USD 9.18 billion in 2025 and is projected to grow to USD 9.84 billion in 2026, with a CAGR of 8.04%, reaching USD 15.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.18 billion
Estimated Year [2026] USD 9.84 billion
Forecast Year [2032] USD 15.78 billion
CAGR (%) 8.04%

A concise yet compelling introduction to the evolving atopic dermatitis therapeutic landscape, highlighting scientific advances, unmet needs, and strategic priorities

Atopic dermatitis has evolved from a predominantly symptomatic dermatology problem to a complex therapeutic area with multiple disease-modifying aspirations. Advances in immunology have clarified key driver pathways, enabling therapies that target interleukin signaling and Janus kinase pathways, while improvements in topical formulations and delivery technologies have enhanced adherence and tolerability. Concurrently, payer scrutiny, real-world safety evidence, and patient expectations are reshaping how new and existing therapies are prioritized for clinical adoption.

Against this backdrop, stakeholders must translate scientific progress into practical strategies that address heterogenous patient presentations, divergent regulatory environments, and shifting commercial models. This introduction sets out the clinical, regulatory, and commercial forces that inform strategic decision-making across developers, payers, providers, and distribution partners. By framing the therapeutic landscape in terms of innovation trajectories and access considerations, readers can appraise where incremental improvements deliver the greatest value and where transformational interventions alter long-term care models.

Transformative shifts reshaping atopic dermatitis care delivery and treatment paradigms driven by biologics, small molecules, digital health, and reimbursement pressures

The atopic dermatitis landscape is experiencing transformative shifts that affect discovery, development, and commercialization pathways. Biologic therapies targeting specific cytokines have set a new standard for moderate-to-severe disease control, which in turn has catalyzed investment in both next-generation biologics and oral small molecules designed for broader patient populations. Meanwhile, safety narratives and post-marketing evidence for small molecule immunomodulators are influencing regulatory dialogues and clinical guidelines, prompting manufacturers to refine labeling, surveillance strategies, and patient selection criteria.

In parallel, non-clinical forces are changing the way products reach patients. Digital health tools are improving remote diagnosis and adherence monitoring, leading to more data-driven care pathways. Distribution innovations are also emerging, with online pharmacies and e-commerce platforms extending reach and enabling differentiated service models. Reimbursement models are pivoting toward outcomes-based arrangements in some systems, encouraging payers and manufacturers to align on value metrics. Therefore, companies that integrate therapeutic differentiation with digital patient support and robust evidence generation will likely gain sustained traction as treatment paradigms continue to shift.

Scenario-based cumulative impact analysis of potential United States tariffs in 2025 on supply chains, pricing dynamics, clinical access, and manufacturing strategies

If new tariff measures are enacted in 2025, cumulative effects would reverberate across manufacturing, procurement, and patient access pathways in the atopic dermatitis drug ecosystem. Active pharmaceutical ingredients and certain specialized excipients are sourced through complex international supply chains that include major production hubs. Tariff-induced cost increases on inputs could prompt manufacturers to reassess supplier portfolios, accelerate nearshoring initiatives, or renegotiate contractual terms to sustain product affordability and supply continuity. Importantly, these supply-side responses would unfold alongside distributor and wholesaler strategies to mitigate margin compression while maintaining inventory flow.

Moreover, tariffs can indirectly influence clinical and commercial decisions. Higher input or finished-goods costs may pressure pricing and payer negotiations, leading to tighter utilization management and more stringent prior authorization criteria. As a result, firms may intensify investments in manufacturing redundancy, enhance transparency on product provenance, and prioritize formulations or presentations with lower import dependencies. In response, health systems and payers could pursue cost-containment measures and incentivize therapies with defined real-world effectiveness. Consequently, a proactive approach that integrates procurement resilience, manufacturing localization, and stakeholder engagement becomes critical to managing the cumulative implications of tariff policy shifts.

Segment-focused insights revealing how drug class, route and mode of administration, distribution channels, and patient age cohorts drive clinical adoption and commercial tactics

A granular segmentation lens reveals how clinical attributes and commercial mechanics shape therapeutic adoption and patient outcomes. When products are examined by drug class, systemic therapies split into biologics and small molecule immunosuppressants, while topical options cover calcineurin inhibitors, corticosteroids, phosphodiesterase 4 inhibitors, and vitamin D analogues, each presenting distinct efficacy-safety profiles and adherence considerations. Consequently, strategic planning must recognize that biologics often demand infrastructure for injectable delivery and monitoring, whereas topical agents require sustained patient education and formulation innovation to improve cutaneous penetration and tolerability.

Turning to route of administration, formulations such as creams, gels, lotions, and ointments determine patient experience and regimen adherence, with rheology and excipient selection influencing both efficacy and sensory acceptability. Regarding mode of administration, the dichotomy between injectable and oral treatments poses different clinical and logistical implications; injectables further bifurcate into pre-filled syringes and vials, which affect cold-chain requirements, administration training, and provider workflows. Distribution channels also warrant careful segmentation analysis because hospital pharmacies, online pharmacies, and retail pharmacies each play distinct roles in access and service delivery; hospital pharmacies include private and public institutions with different procurement cycles, online pharmacies operate through digital health platforms and e-commerce channels that enable direct-to-patient models, and retail pharmacies comprise chain and independent operators with varying dispensing practices and patient touchpoints. Finally, patient age grouping into adult, geriatric, and pediatric cohorts underpins clinical trial design, dosing strategies, safety monitoring, and market messaging, since each cohort has unique physiology, comorbidity patterns, and caregiver dynamics that influence treatment selection and adherence. Integrating these segmentation dimensions provides a multi-faceted view that informs product positioning, clinical development prioritization, and channel-specific commercialization tactics.

Regional landscape interpretation comparing the Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics influencing regulation, access, and strategic partnerships in AD care

Regional dynamics shape regulatory approaches, payer expectations, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, each presenting distinctive strategic imperatives. In the Americas, regulatory pathways and payer systems favor evidence demonstrating meaningful patient-level benefits, and there is growing interest in real-world data to validate long-term safety and function. Stakeholders operating in this region must navigate a fragmented payer landscape while building strong value narratives and post-launch evidence platforms to support formulary access and treatment continuity.

By contrast, Europe, Middle East & Africa encompasses a diverse set of regulatory and reimbursement environments where centralized approvals coexist with national-level pricing negotiations and local tender practices. Market entry strategies here benefit from adaptive evidence generation and local partnerships that account for heterogeneous health technology assessment frameworks. In the Asia-Pacific region, rapid adoption of innovative therapies in certain markets coexists with constrained access in others, creating a tiered approach to commercialization that blends regional licensing, pricing flexibility, and capacity-building collaborations. Across all regions, cross-border partnerships, supply chain resilience, and culturally adapted patient engagement approaches will be essential to align therapeutic innovation with local health system priorities.

Corporate competitive intelligence revealing how leading pharmaceutical and biotech companies are advancing pipelines, partnerships, and commercialization strategies in atopic dermatitis

Leading companies are converging on a few clear strategic motifs: differentiated science, pragmatic evidence generation, and ecosystem partnerships. Firms advancing biologic programs emphasize target validation, head-to-head tolerability advantages, and long-term safety monitoring to distinguish their offerings from both established products and new entrants. Similarly, developers of small molecule immunomodulators are refining dose optimization, monitoring strategies, and risk-management plans to address safety sensitivities and to broaden label applicability across adult and pediatric cohorts. In parallel, companies focusing on topical therapies pursue formulation science that improves skin penetration, reduces irritation, and supports patient adherence through more cosmetically acceptable presentations.

Commercially, organizations are investing in digital patient support programs, clinician education, and coordinated care models that integrate dermatology, allergy, and primary care perspectives. Partnerships with specialty distributors, digital health platforms, and pharmacy networks allow companies to diversify access pathways and tailor service models to different patient segments. Additionally, M&A and licensing are being used selectively to acquire niche technologies or to secure manufacturing capacity that reduces supply-chain exposure. Collectively, these strategies indicate that success in atopic dermatitis will depend on aligning clinical differentiation with pragmatic deployment models that anticipate regulatory scrutiny and payer demands for demonstrable, sustained patient benefit.

Practical, high-impact recommendations for industry leaders to optimize R&D prioritization, supply resilience, pricing strategies, and patient-centric commercialization in AD

Industry leaders should prioritize a set of actionable initiatives that align scientific opportunity with practical implementation. First, invest in differentiated clinical development strategies that pair mechanistic rationale with robust safety surveillance and real-world evidence plans; this will facilitate regulatory engagement and payer dialogues while supporting clinician confidence. Second, fortify supply-chain resilience by diversifying supplier bases, evaluating nearshore manufacturing options, and embedding contingency planning into procurement contracts to mitigate external policy or logistical shocks.

Third, design commercialization models that combine product differentiation with digital patient support to improve adherence and outcomes. This includes integrating teledermatology, remote monitoring, and adherence coaching to extend the reach of specialty therapies. Fourth, engage payers proactively with clear value propositions framed around clinically meaningful endpoints and patient-reported outcomes to reduce utilization friction. Finally, adopt flexible pricing and access strategies that accommodate regional differences and enable pilot outcomes-based arrangements where appropriate. Collectively, these steps will help organizations translate therapeutic innovation into accessible, sustainable care pathways.

Robust research methodology description that explains data sources, analytical approaches, validation protocols, and how insights were synthesized for actionable industry guidance

The analysis underpinning this report synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, company disclosures, and longitudinal safety datasets to construct a comprehensive evidence base. Qualitative inputs from clinician thought leaders, payer advisors, and supply-chain experts were integrated through structured interviews to contextualize quantitative findings and to surface operational implications. Analytical approaches combined thematic synthesis with scenario analysis to explore policy, pricing, and supply-chain contingencies and their implications for clinical adoption and access.

To ensure robustness, validation protocols included cross-referencing regulatory submissions and published trial outcomes, triangulating expert opinions across geographies, and stress-testing strategic hypotheses against alternative policy scenarios. Confidential primary research complemented secondary sources to capture evolving commercial tactics and channel innovations. This mixed-methods approach ensures that the insights are actionable for strategy teams, clinical development planners, and commercial leaders seeking evidence-informed decisions.

Concluding synthesis that distills key strategic takeaways, risk considerations, and opportunity windows for stakeholders across clinical, regulatory, and commercial functions

In closing, the atopic dermatitis therapeutics landscape is defined by rapid scientific progress, shifting access dynamics, and an increasingly complex interplay between clinical differentiation and commercial execution. Strategic winners will be those that pair compelling mechanistic advantages with executable plans for evidence generation, manufacturing reliability, and channel-specific patient engagement. Risk considerations include safety surveillance requirements for novel modalities, policy shifts that affect supply chains and pricing, and the need to tailor approaches across diverse regional health systems.

However, opportunities are abundant for organizations that proactively align pipeline priorities with pragmatic delivery models, invest in real-world evidence, and foster partnerships that bridge clinical innovation with operational scale. By synthesizing clinical, regulatory, and commercial perspectives into coherent strategies, stakeholders can navigate the contested terrain between innovation and access to deliver better outcomes for patients living with atopic dermatitis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atopic Dermatitis Drugs Market, by Drug Class

  • 8.1. Systemic
    • 8.1.1. Biologics
    • 8.1.2. Small Molecule Immunosuppressants
  • 8.2. Topical
    • 8.2.1. Calcineurin Inhibitors
    • 8.2.2. Corticosteroids
    • 8.2.3. PDE4 Inhibitors
    • 8.2.4. Vitamin D Analogues

9. Atopic Dermatitis Drugs Market, by Route Of Administration

  • 9.1. Cream
  • 9.2. Gel
  • 9.3. Lotion
  • 9.4. Ointment

10. Atopic Dermatitis Drugs Market, by Mode Of Administration

  • 10.1. Injectable
    • 10.1.1. Pre Filled Syringes
    • 10.1.2. Vials
  • 10.2. Oral

11. Atopic Dermatitis Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Atopic Dermatitis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
    • 12.1.1. Private Hospital Pharmacies
    • 12.1.2. Public Hospital Pharmacies
  • 12.2. Online Pharmacies
    • 12.2.1. Digital Health Platforms
    • 12.2.2. E Commerce Platforms
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. Atopic Dermatitis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atopic Dermatitis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atopic Dermatitis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Atopic Dermatitis Drugs Market

17. China Atopic Dermatitis Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Almirall, S.A.
  • 18.7. Amgen Inc.
  • 18.8. Arcutis Biotherapeutics, Inc.
  • 18.9. Bausch Health Companies Inc.
  • 18.10. BiomX Inc.
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Dermavant Sciences Inc.
  • 18.13. Eli Lilly and Company
  • 18.14. Galderma Group AG
  • 18.15. Glenmark Pharmaceuticals Ltd.
  • 18.16. Incyte Corporation
  • 18.17. Intas Pharmaceuticals Ltd.
  • 18.18. Kiniksa Pharmaceuticals, Ltd.
  • 18.19. Kyowa Hakko Kirin Co., Ltd.
  • 18.20. LEO Pharma A/S
  • 18.21. Novartis AG
  • 18.22. Otsuka Holdings Co., Ltd.
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Sun Pharmaceutical Industries Ltd.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. UCB S.A.
  • 18.29. Vanda Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SMALL MOLECULE IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SMALL MOLECULE IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SMALL MOLECULE IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY LOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY LOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRE FILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRE FILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRE FILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DIGITAL HEALTH PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)